The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...
A recent study found that combined tocilizumab and glucocorticoid therapy for at least 6 months did not fully eliminate ...
The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.
Findings showed tocilizumab-anoh had comparable efficacy, pharmacokinetics, safety, and immunogenicity with Actemra. The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab ...
Tocilizumab-anoh is approved for multiple conditions, including rheumatoid arthritis and COVID-19, in intravenous and subcutaneous formulations. Phase 3 study confirmed biosimilarity between ...
GlobalData on MSN12d
Celltrion’s Avtozma receives FDA approval for multiple conditionsThe FDA's approval is grounded in an evidence totality and comprehensive data package, which includes outcomes from a study.
Public health officials are looking into reports of a small potential uptick in neurologic complications of influenza in ...
NYU Langone Health in New York City reportedly cancelled the appointments of two transgender children scheduled to receive ...
The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...
The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback